CAMP4 Therapeutics (NASDAQ:CAMP) Director Sells 114,700 Shares of Stock

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Director Andrew Schwab sold 114,700 shares of the company’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $4.54, for a total value of $520,738.00. Following the completion of the sale, the director owned 2,465,298 shares in the company, valued at approximately $11,192,452.92. This represents a 4.45% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

CAMP4 Therapeutics Price Performance

CAMP traded up $0.02 during trading on Friday, reaching $4.48. 126,663 shares of the company’s stock were exchanged, compared to its average volume of 183,971. CAMP4 Therapeutics Corporation has a 1 year low of $1.41 and a 1 year high of $7.75. The stock has a market capitalization of $281.12 million, a P/E ratio of -1.93 and a beta of 0.22. The company’s fifty day simple moving average is $4.11 and its 200-day simple moving average is $4.33.

CAMP4 Therapeutics (NASDAQ:CAMP) last announced its quarterly earnings data on Thursday, August 13th. The Wireless communications provider reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.34). The business had revenue of $1.78 million for the quarter. CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. Equities analysts forecast that CAMP4 Therapeutics Corporation will post -0.59 EPS for the current year.

Institutional Trading of CAMP4 Therapeutics

A number of hedge funds have recently added to or reduced their stakes in CAMP. Bank of America Corp DE acquired a new stake in CAMP4 Therapeutics during the second quarter valued at $78,000. Trails Edge Capital Partners LP acquired a new position in shares of CAMP4 Therapeutics in the second quarter worth about $8,446,935,000. Jupiter Topco LLC acquired a new position in shares of CAMP4 Therapeutics in the second quarter worth about $27,581,000. 5AM Venture Management LLC purchased a new stake in shares of CAMP4 Therapeutics during the 2nd quarter worth about $25,647,928,000. Finally, BlackRock Inc. purchased a new stake in shares of CAMP4 Therapeutics during the 2nd quarter worth about $7,185,000.

Wall Street Analysts Forecast Growth

CAMP has been the topic of several recent research reports. UBS Group set a $15.00 price target on shares of CAMP4 Therapeutics in a report on Friday, August 14th. JPMorgan Chase & Co. upgraded CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $5.00 to $9.00 in a research note on Tuesday, June 16th. Zacks Research raised CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday. Chardan Capital set a $6.50 target price on CAMP4 Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, June 10th. Finally, Weiss Ratings raised CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 14th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $9.56.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.